Currently, there are an estimated 46 million people worldwide living with dementia. There is currently no cure, and no way to prevent the onset of dementia. The Wayback Project was created by a group of friends and former colleagues who wanted to create virtual reality films that allow patients to go 'back in time'.
Like a great orchestra, your brain relies on the perfect coordination of many elements to function properly. And if one of those elements is out of sync, it affects the entire ensemble. In Alzheimer's disease, for instance, damage to specific neurons can alter brainwave rhythms and cause a loss of cognitive functions.
It's a paradox of Alzheimer's disease: Plaques of the sticky protein amyloid beta are the most characteristic sign in the brain of the deadly neurodegenerative disease. However, many older people have such plaques in their brains but do not have dementia.
African Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center.
A compound in beets that gives the vegetable its distinctive red color could eventually help slow the accumulation of misfolded proteins in the brain, a process that is associated with Alzheimer's disease. Scientists say this discovery could lead to the development of drugs that could alleviate some of the long-term effects of the disease, the world's leading cause of dementia.
A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enough, a daily regimen of the non-prescription NSAID (nonsteroidal anti-inflammatory drug) ibuprofen can prevent the onset of Alzheimer's disease.
Years before people start showing characteristic symptoms of Alzheimer's disease, sticky plaques begin forming in their brains, damaging nearby cells. For decades, doctors have sought ways to clear out these plaques as a way to prevent or treat the disease.
You're about to turn 60, and you're fretting. Your mother has had Alzheimer's disease since the age of 65. At what age will the disease strike you? A Canadian study published in JAMA Neurology shows that the closer a person gets to the age at which their parent exhibited the first signs of Alzheimer's, the more likely they are to have amyloid plaques, the cause of the cognitive decline associated with the disease, in their brain.
Although certain genetic variants increase the risk of Alzheimer's disease (AD), age is the strongest known risk factor. But the way in which molecular processes of aging predispose people to AD, or become impaired in AD remains a mystery.
A team of researchers from the Cleveland Clinic Lerner Research Institute have found that gradually depleting an enzyme called BACE1 completely reverses the formation of amyloid plaques in the brains of mice with Alzheimer's disease, thereby improving the animals' cognitive function.
A therapeutic target to preserve vision in glaucoma patients could have treatment ramifications for age-related neurodegenerative disorders like Alzheimer's and Parkinson's, according to findings released today in the Proceedings of the National Academy of Sciences.
An association between inflammation biomarkers in both blood plasma and cerebrospinal fluid and markers of Alzheimer's disease associated pathology, has been found by researchers at the University of Colorado Anschutz Medical Campus working with the University of Wisconsin Alzheimer's Disease Research Center and the University of California San Francisco Memory and Aging Center.
Stigma associated with Alzheimer's disease may be an obstacle for individuals to seek information about their risk of developing Alzheimer's disease and to participate in clinical studies that discover potential therapies.
A new report shows that Alzheimer’s disease cases and the costs of treatment and hospitalization due to this disease and deaths due to this condition are on the rise. The report finds that at present 5.7 million Americans suffer from Alzheimer’s disease and of these 5.5 million are over the age of 65 years. Of these 3.4 million are women.
In a new study, researchers have shown that excessive sleepiness during the day time among elderly who had normal mental acuity and cognitive powers is associated with the buildup of amyloid plaques in the brain that is typical of Alzheimer’s disease.
Because people are now living longer and often healthier lives, the rate of some illnesses that are more likely to develop with age has risen. These illnesses include dementia. In fact, the number of us living with dementia was already 47 million worldwide in 2015. It could reach 131 million by 2050.
Alzheimer´s disease is the key cause of dementia in elderly patients. Those affected develop deficiencies in their abilities to learn, think logically, communicate, and to master the challenges of everyday life.
Sanford Burnham Prebys Medical Research Institute researchers have published two new studies in Neuron that describe how TREM2, a receptor found on immune cells in the brain, interacts with toxic amyloid beta proteins to restore neurological function.
A research conducted by the UAB demonstrates that mice suffering from this disease also have substantial malfunctions in small blood vessels, important in nourishing different organs and tissues and in regulating blood pressure, and which mainly affects females.
AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.
Scientists at Wake Forest Baptist Medical Center and the University of Southern California (USC) have demonstrated the successful implementation of a prosthetic system that uses a person's own memory patterns to facilitate the brain's ability to encode and recall memory.
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||